HomeCompareAGYTF vs EPRT

AGYTF vs EPRT: Dividend Comparison 2026

AGYTF yields 1818.18% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AGYTF wins by $4103414683.77M in total portfolio value
10 years
AGYTF
AGYTF
● Live price
1818.18%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4103414683.84M
Annual income
$3,702,796,788,756,407.00
Full AGYTF calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — AGYTF vs EPRT

📍 AGYTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGYTFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGYTF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AGYTF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGYTF
Annual income on $10K today (after 15% tax)
$154,545.45/yr
After 10yr DRIP, annual income (after tax)
$3,147,377,270,442,946.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, AGYTF beats the other by $3,147,377,270,431,751.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGYTF + EPRT for your $10,000?

AGYTF: 50%EPRT: 50%
100% EPRT50/50100% AGYTF
Portfolio after 10yr
$2051707341.95M
Annual income
$1,851,398,394,384,789.00/yr
Blended yield
90.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

AGYTF
No analyst data
Altman Z
-5.5
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGYTF buys
0
EPRT buys
0
No recent congressional trades found for AGYTF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGYTFEPRT
Forward yield1818.18%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$4103414683.84M$64.3K
Annual income after 10y$3,702,796,788,756,407.00$13,170.85
Total dividends collected$4074760433.31M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: AGYTF vs EPRT ($10,000, DRIP)

YearAGYTF PortfolioAGYTF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$192,518$181,818.18$11,212$512.01+$181.3KAGYTF
2$3,477,331$3,271,336.99$12,689$692.09+$3.46MAGYTF
3$58,943,217$55,222,471.89$14,521$944.30+$58.93MAGYTF
4$937,891,469$874,822,227.57$16,841$1,302.88+$937.87MAGYTF
5$14,012,869,532$13,009,325,660.38$19,841$1,821.64+$14012.85MAGYTF
6$196,647,994,247$181,654,223,846.76$23,818$2,587.47+$196647.97MAGYTF
7$2,592,865,386,485$2,382,452,032,641.56$29,230$3,744.65+$2592865.36MAGYTF
8$32,132,661,421,271$29,358,295,457,731.54$36,816$5,540.38+$32132661.38MAGYTF
9$374,409,247,740,494$340,027,300,019,734.44$47,806$8,413.17+$374409247.69MAGYTF
10$4,103,414,683,838,736$3,702,796,788,756,407.00$64,324$13,170.85+$4103414683.77MAGYTF

AGYTF vs EPRT: Complete Analysis 2026

AGYTFStock

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

Full AGYTF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this AGYTF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGYTF vs SCHDAGYTF vs JEPIAGYTF vs OAGYTF vs KOAGYTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.